Shandong Lukang Pharmaceutical (600789.SH) has received approval from the China Securities Regulatory Commission to issue stocks to specific entities.

18:32 29/09/2025

LuKang Pharmaceutical (600789.SH) released an announcement, stating that the company has recently received a notice from the China Securities Regulatory Commission (referred to as "CSRC" for short)...

Shandong Lukang Pharmaceutical (600789.SH) has announced that the company has recently received approval from the China Securities Regulatory Commission (referred to as the "CSRC") for the registration of issuing stocks to specific investors. The approval is granted in the document titled "Approval for Shandong Lukang Pharmaceutical Co., Ltd. to Issue Stocks to Specific Investors" (CSRC Permit [2025] 2158). The company's registration application to issue stocks to specific investors has been approved.

New Stock Analysis | Wangshan Wangshui: From 6.42 million profit to 2.18 billion loss, the cash flow cliff and the hundred billion market gamble behind nine pipelines.

Guosheng Securities: It is almost certain that the Federal Reserve will continue to cut interest rates in October and December. It is expected that there will be three more rate cuts in 2026.

CMSC: Hong Kong stocks return to growth style after adjustment, focusing on internet and insurance.

New Stock Analysis | Wangshan Wangshui: From 6.42 million profit to 2.18 billion loss, the cash flow cliff and the hundred billion market gamble behind nine pipelines.

Guosheng Securities: It is almost certain that the Federal Reserve will continue to cut interest rates in October and December. It is expected that there will be three more rate cuts in 2026.

CMSC: Hong Kong stocks return to growth style after adjustment, focusing on internet and insurance.